BREAKING NEWS: Remdesivir has ‘little effect’ on COVID-19 death risks, WHO study study finds
- The antiviral remdesivir is one of just two COVID-19 treatments that has emergency FDA approval in the US
- A WHO trial of 11,266 hospitalized COVID-19 patients tested remdesivir, hydroxychloroquine, lopinavir and interferon treatments
- The SOLIDARITY trial found that none of the four ‘substantially affected’ mortality rates
More than 11,200 hospitalized COVI-19 patients around the world were treated with remdesivir – an antiviral – lopinavir, hydroxychloroquine, interferon or a placebo for the WHO’s massive SOLIDARITY trial.
None of the drugs ‘substantially affected’ mortality risks, the dismal report found.
It’s a blow to hopes that the world is getting better at treating people sickened by the pandemic that has claimed the lives of more than a million people globally, including more than 217,000 in the US.
SOLIDARITY’s findings are particularly grim news for the US, where remdesivir is one of just two treatments to have gotten emergency Food and Drug Administration (FDA) authorization.
US government research suggested the drug improved survival odds and shortened recovery times.
The federal government has already amassed a stockpile of the drug, and regulators revoked emergency approval for another drug found ineffective for treating coronavirus by the WHO trial, hydroxychloroquine, in June.
This is a developing story.
A massive WHO study found that remdesivir had no significant effect on COVID-19 death risks